IP Library Granted Patent US 8,143,372
Granted Patent B2
US 8,143,372 · App. 12/122,469 · Granted Mar 27, 2012

Synthetic regulators of ferritin protein nanocage pores and methods of use thereof

Assignee: Children's Hospital & Research Center Oakland
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,372
App. No.
12/122,469
Granted
Mar 27, 2012
Kind
B2
Abstract

The present invention provides synthetic regulators of ferritin pores, and compositions comprising the regulators. The regulators function to reduce ferritin demineralization rates. The regulators are useful for treating inflammatory conditions. The present invention also provides methods of treating inflammatory conditions. The present invention further provides synthetic regulators of bacterial mini-ferritins; such regulators are useful as antibacterial agents.

Claims (11)

1. A synthetic peptide comprising a ferritin protein nanocage pore-binding moiety, wherein said synthetic peptide has a length of from about 7 amino acids to about 50 amino acids, wherein the peptide comprises the amino acid sequence HHALDGS (SEQ ID NO:1), and wherein said ferritin protein nanocage pore binding moiety reduces the rate of iron release from ferritin.

2. The peptide of claim 1 , wherein said peptide has a length of from about 7 amino acids to about 25 amino acids.

3. A pharmaceutical composition comprising:

a) a synthetic peptide according to claim 1 ; and

b) a pharmaceutically acceptable excipient.

4. The composition of claim 3 , wherein said composition is an injectable composition.

5. A method of reducing inflammation in an individual, the method comprising administering to the individual an effective amount of a composition of claim 3 .

6. The method of claim 5 , wherein the inflammation is associated with allergy.

7. The method of claim 5 , wherein the inflammation is associated with an autoimmune disorder.

8. The synthetic peptide of claim 1 , wherein the synthetic peptide comprises the amino acid sequence HSHHALDGSGG (SEQ ID NO:2).

9. The synthetic peptide of claim 1 , wherein the synthetic peptide comprises a sequence of from 1 to 12 arginine residues at the carboxyl and/or amino terminus.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 16, 2009
From: CHILDREN'S HOSPITAL AND RESEARCH CENTER OAKLAND INSTITUTION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023661/0947 →
CONFIRMATORY LICENSE Recorded Sep 29, 2009
From: CHILDREN'S HOSPITAL & RES CTR AT OAKLAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023295/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2008
From: THEIL, ELIZABETH
To: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
Reel/Frame 021375/0991 →
Continuity (2)
Provisional Application 60939133 · May 21, 2007
Related Publication 20090325869A1 · Dec 31, 2009